Quick Answer
Arcutis Biotherapeutics, Inc. reported Diluted EPS of $0.13 per share (loss) for fiscal year 2025.
Arcutis Biotherapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.13 | +88.8% |
| 2024 | -$1.16 | +69.3% |
| 2023 | -$3.78 | +33.2% |
| 2022 | -$5.66 | -35.4% |
| 2021 | -$4.18 | -10.0% |
| 2020 | -$3.80 | +83.3% |
| 2019 | -$22.78 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.06 | +118.2% | +146.2% |
| June 30, 2025 | -$0.13 | +69.0% | +35.0% |
| March 31, 2025 | -$0.20 | +37.5% | +39.4% |
| September 30, 2024 | -$0.33 | +54.8% | +21.4% |
| June 30, 2024 | -$0.42 | +63.8% | -31.2% |
| March 31, 2024 | -$0.32 | +75.6% | +56.2% |
| September 30, 2023 | -$0.73 | +61.4% | +37.1% |
| June 30, 2023 | -$1.16 | +11.5% | +11.5% |
- Arcutis Biotherapeutics, Inc. showed an increase of +88.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Arcutis Biotherapeutics, Inc.’s diluted eps has grown by 99.4% (from $22.78 per share (loss) to $0.13 per share (loss)).
- The most recent figure is from Arcutis Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: